Racing against the clock, Stada Arzneimittel AG's executive board has voiced worry that the second takeover offer from two private equity suitors will also fail, leaving the German generics maker without a clear future.
With the deadline for acceptances just days away, Stada's leadership has issued an open letter imploring shareholders not to sit on their hands but to accept the improved €4